+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus



Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus



Journal of Infectious Diseases 180(2): 268-277



Two human monoclonal antibodies, RF-1 and RF-2, specifically recognize the fusion protein of the human respiratory syncytial virus (RSV). These were isolated from spontaneous tumors in SCID mice reconstituted with human splenocytes and boosted with fusion protein. The tumors consisted of Epstein-Barr virus-transformed human B cells in animals with antigen-specific antibody titers>105. The binding affinity of RF-1 and RF-2 to the fusion protein is 1010 and 109 M-1, respectively. The antibodies bind specifically to a conformational epitope of the fusion protein on RSV-infected HEp-2 cells. Both antibodies display virus-neutralizing properties in vitro at concentrations varying between 8 and 1000 ng/mL. Virus neutralization applies to a broad variety of wild and laboratory-adapted virus strains belonging to both virus types A and B. These antibodies are potential candidates for passive immunotherapy of severe RSV infections.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010767247

Download citation: RISBibTeXText

PMID: 10395839

DOI: 10.1086/314876


Related references

Human Monoclonal Antibodies Isolated from Spontaneous Epstein-Barr Virus-Transformed Tumors of Hu-Spl-Scid Mice and Specific for Fusion Protein Display Broad Neutralizing Activity toward Respiratory Syncytial Virus. The Journal of Infectious Diseases 180(2): 268-277, 1999

Two neutralizing human monoclonal antibodies, specific for fusion protein of respiratory syncytial virus, isolated from hu-SCID mice. FASEB Journal 10(6): A1465, 1996

A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. Journal of Virology 71(6): 4347-4355, 1997

Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation. Virology 460-461: 119-127, 2014

Efficient generation of respiratory syncytial virus -neutralizing human MoAbs via human peripheral blood lymphocyte -SCID mice and scFv phage display libraries. Clinical & Experimental Immunology 122(1): 85-93, 2000

Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries. Clinical and Experimental Immunology 122(1): 85-93, 2000

Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. Open Virology Journal 6: 12-22, 2012

Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli. Journal of General Virology 74: 2559-2565, 1993

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. Journal of General Virology 73: 2225-2234, 1992

Human monoclonal antibodies produced by Epstein-Barr virus transformed cell lines bind protein A. Immunology Letters 9(1): 19-22, 1985

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Virology 454-455: 139-144, 2014

Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Journal of General Virology 68: 1575-1586, 1987

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. Journal of Virology 84(16): 8132-8140, 2010

Generation of human anti-rubella monoclonal antibodies from human hybridomas constructed with antigen-specific Epstein-Barr virus transformed cell lines. Behring Institute Mitteilungen 1986(80): 31-41, 1986

Occurrence of Epstein-Barr virus deoxyribonuclease enzyme activity-neutralizing antibodies. An index of Epstein-Barr virus disease. Intervirology 30(1): 36-43, 1989